MMA
IBRX icon

Miracle Mile Advisors’s ImmunityBio IBRX Stock Holding History

Miracle Mile Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Sell
21,650
-100
-0.5% -$685 ﹤0.01% 863
2025
Q4 		$43.1K Sell
21,750
-14,950
-41% -$33.9K ﹤0.01% 862
2025
Q3 		$90.3K Buy
36,700
+7,845
+27% +$20.2K ﹤0.01% 813
2025
Q2 		$76.2K Buy
+28,855
New +$77.6K ﹤0.01% 711

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Miracle Mile Advisors's IBRX Position: Q1 2026 in Review

Miracle Mile Advisors reduced its ImmunityBio (IBRX) stake by 0.46% in Q1 2026, selling an estimated $685 and leaving 21,650 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Miracle Mile Advisors first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Miracle Mile Advisors held 21,650 shares of ImmunityBio worth $166K as of Q1 2026.
  • Miracle Mile Advisors sold 100 ImmunityBio shares in Q1 2026, an estimated $685.
  • ImmunityBio made up ﹤0.01% of Miracle Mile Advisors's portfolio in Q1 2026, its #863 holding.
  • Miracle Mile Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Miracle Mile Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.